Indicadores do uso de medicamentos na atenção primária de saúde: uma revisão sistemática

Objective.

To analyze the rational use of medicines in the context of primary health care (PHC) according to the indicators recommended by the World Health Organization (WHO).

Method.

A systematic review of the literature was performed following PRISMA guidelines to synthesize the evidence produced by the application of drug use indicators in PHC in the period from 2011 to 2016. The following databases were searched: PudMed, SciELO and Google Scholar, Virtual Health Library/BIREME, and Portal de Periódicos CAPES, using the keywords “World Health Organization,” “indicators,” “drug utilization,” and “rational use of drugs” in Portuguese and English. Original articles describing studies performed at the PHC level, using at least one of the three sets of indicators (prescription, service-related, or health care) were included.

Results.

Of the 16 studies included, 56.2% were prospective, 37.5% were developed at a local level, 62.5% employed convenience sampling, 56.2% lasted up to 6 months, and 43.8% were performed in Brazil. Prescription indicators were used most (87.5%), followed by service-related indicators (37.5%) and health care indicators (31.3%). None of the scenarios described in the articles fully met the WHO recommendations. The most frequent interventions suggested to resolve the problems related to the rational use of medications included continuing education for rational prescription (56.3%), use of updated lists of essential medicines, including generic drug names and reflecting the needs of the population (31.3%), and implementation of clinical protocols to standardize therapeutic management (31.3%).

Conclusions.

Application of the WHO indicators revealed irrational practices of drug use in PHC in several countries.

Quality of life of patients with rheumatoid arthritis under biological therapy

Summary Objective: assessing health-related quality of life (HRQL) in patients with rheumatoid arthritis (RA), before and after treatment with biological therapy. Methods: a longitudinal study, conducted from November 2010 to September 2011, with implementation of the instruments HAQ II (health assessment questionnaire) and SF-36 (medical outcomes short-from health survey). Barlett test, Anova, Friedman and paired t-test were performed for multiple extracts. Results: 30 patients were evaluated, mean age of 47.6 (SD: 12.25) years and prevalence of females (90%). The mean score of HAQ II before treatment was 1.97, with significant reduction of up to 1.23 after six months of biological therapy (p<0.01). Most of the SF-36 domains showed significant improvement after six months of treatment (p<0.01), highlighting the social aspects, pain, physical functioning, emotional issues, vitality and physical aspects. Conclusion: the use of biologic therapy in patients with RA refractory to standard therapies proved to be an important pharmacological strategy for improving HRQL.